Gene therapy firm MeiraGTx's 2025 net loss narrows

MeiraGTx Holdings

26/03/2026 12:12

Overview

UK-US genetic medicines firm's 2025 revenue surged

Company reported a narrower net loss for 2025 compared to prior year

Outlook

MeiraGTx believes it has capital to fund operations into H2 2027, excluding potential milestone payments

Result Drivers

LILLY COLLABORATION - License revenue increased due to a $75 mln upfront payment from Eli Lilly for the AAV-AIPL1 program and related assets

SERVICE REVENUE DECLINE - Service revenue and related costs fell as Johnson & Johnson manufacturing work was substantially completed in H1 2025

R&D SPENDING - Research and development expenses rose due to increased manufacturing costs and higher activity in clinical and preclinical programs, partly offset by lower AAV-hAQP1 costs

Company press release: ID:nGNX312C4s

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.42
FY Net Income
-$114.20 mln
FY Income from Operations
-$105.97 mln
FY Operating Expenses
$187.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $29.00, about 280.6% above its March 25 closing price of $7.62

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)